RESUMEN

Cr release overtime was investigated in batch experiments for eleven air-pollution-control residues from eight different municipal solid waste incinerators covering all majorflue gas cleaning technologies. Cr released during 168 h of contact with water showed significant variations among the residues studied. Also for the individual residue, large variations were observed depending on the liquid-to-solid ratio used in the leaching test and the degree of carbonation. It is argued that Al(0) present in the residues can control Cr leaching by reducing Cr(VI) released from the solid phase by dissolution and that exposure to oxygen-either prior to or during the leaching test-depletes the reduction capacity of Al(0) leading to increased Cr leaching. A dynamic model is shown to describe Cr release from all investigated residues by accounting for Al(0) oxidation with Cr(VI), O2, and water as well as Cr(VI) dissolution. The paper reveals that Al-O2-Cr(VI) interactions must be considered very carefully when interpreting Cr leaching data.

Asunto(s)

Contaminantes Atmosféricos/análisis , Cromo/análisis , Incineración , Contaminación del Aire/prevención & control , Carcinógenos Ambientales/análisis , Oxidación-Reducción

RESUMEN

We characterized organotypic ventral mesencephalic (VM) cultures derived from embryonic day 12 (E12) mice (CBL57/bL6) in terms of number of dopaminergic neurons, cell soma size and dopamine production in relation to time in vitro and tested the effects of 1-methyl-4-phenylpyridinium (MPP(+)) and glial derived neurotrophic factor (GDNF) to validate this novel culture model. Dopamine production and dopaminergic neuron soma size increased dramatically with time in vitro, whereas the number of dopamine neurons declined by approximately 30% between week 1 and week 2, which was further reduced after week 4. GDNF treatment (100 ng/mL) increased dopaminergic neuron soma size (up to 43%) and DOPAC production (approximately three-fold), but not the number of dopamine neurons in control cultures. One-week-old cultures were more vulnerable to MPP(+), than three-week-old cultures. The EC(50) for dopamine depletion after 2 days exposure and 15 days of recovery were 0.6 and 7 microm, respectively. Both pre-treatment and post-treatment with GDNF are important to obtain maximal protection against MPP(+) toxicity. In one-week-old cultures (5 microm MPP(+), 2 days) GDNF provided potent neuroprotection with dopamine contents reaching control levels and number of tyrosine hydroxylase (TH)(+) cells up to 80% of control, but in three-week-old cultures (10 microm MPP(+), 2 days) the protective potential of GDNF was markedly reduced. Long recovery periods after MPP(+) exposure are required to distinguish between reversible or irreversible toxic and/or trophic effects.

Asunto(s)

1-Metil-4-fenilpiridinio/antagonistas & inhibidores , Degeneración Nerviosa/tratamiento farmacológico , Factores de Crecimiento Nervioso/farmacología , Fármacos Neuroprotectores/farmacología , Trastornos Parkinsonianos/tratamiento farmacológico , Sustancia Negra/efectos de los fármacos , 1-Metil-4-fenilpiridinio/toxicidad , Ácido 3,4-Dihidroxifenilacético/metabolismo , Animales , Diferenciación Celular/efectos de los fármacos , Diferenciación Celular/fisiología , Proliferación Celular/efectos de los fármacos , Tamaño de la Célula/efectos de los fármacos , Células Cultivadas , Modelos Animales de Enfermedad , Dopamina/metabolismo , Relación Dosis-Respuesta a Droga , Factor Neurotrófico Derivado de la Línea Celular Glial , Ratones , Ratones Endogámicos C57BL , Degeneración Nerviosa/metabolismo , Degeneración Nerviosa/prevención & control , Factores de Crecimiento Nervioso/uso terapéutico , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Fármacos Neuroprotectores/uso terapéutico , Neurotoxinas/antagonistas & inhibidores , Neurotoxinas/toxicidad , Técnicas de Cultivo de Órganos , Trastornos Parkinsonianos/metabolismo , Trastornos Parkinsonianos/fisiopatología , Recuperación de la Función/efectos de los fármacos , Recuperación de la Función/fisiología , Sustancia Negra/metabolismo , Sustancia Negra/fisiopatología , Factores de Tiempo , Tirosina 3-Monooxigenasa/efectos de los fármacos , Tirosina 3-Monooxigenasa/metabolismo

RESUMEN

Ex vivo gene transfer to the CNS has so far been hampered by instability of transgene expression. To avoid the phenomenon of transgene down-regulation, we have employed strong, constitutive promoters and compared this expression system with the inducible Tet expression system incorporated in a single plasmid vector or in lentiviral vectors. Plasmid-based transgene expression directed by the constitutive, human ubiquitin promoter, UbC, was stable in transfected HiB5 cells in vitro and comparable in strength to the CMV promoter. However, after transplantation of UbC and CMV HiB5 clones to the rat striatum, silencing of the transgene occurred in most cells soon after implantation of transfected cells. The Tet-on elements were incorporated in a single plasmid vector and inducible HiB5 clones were generated. Inducible clones displayed varying basal expression activity, which could not be ascribed to an effect of cis-elements in the vector, but rather was due, at least in part, to intrinsic activity of the minimal promoter. Basal expression activity could be blocked in a majority of cells by stable expressing the transrepressor tTS. Fully induced expression levels were comparable to CMV and UbC promoters. Similar to the constitutive promoters transgene expression was down-regulated soon after grafting of inducible HiB5 clones to the rat striatum. Lentiviral vectors can direct long-term stable in vivo transgene expression. To take advantage of this quality of the lentiviral vector, the Tet-on elements were incorporated in two lentiviral transfer vectors followed by transduction of Hib5 cells. Interestingly, all HiB5 clones established by lentiviral transduction showed very similar expression patterns and tight regulatability that apparently was independent of transgene copy number and integration site. Nevertheless, transgene expression in all lentiviral HiB5 clones was down-regulated shortly after transplantation to the rat striatum. These results confirm the general phenomenon of transgene down-regulation. Moreover, the results suggest that the considerable advantages offered by lentiviral vectors for direct gene delivery cannot necessarily be transferred directly to ex vivo gene delivery. This emphasizes the need for alternative vector strategies for ex vivo gene transfer.

Asunto(s)

Encéfalo/metabolismo , Regulación hacia Abajo , Silenciador del Gen , Técnicas de Transferencia de Gen , Proteínas Represoras/metabolismo , Animales , Citomegalovirus/genética , Femenino , Vectores Genéticos , Humanos , Lentivirus/genética , Microscopía Fluorescente , Plásmidos/genética , Regiones Promotoras Genéticas , Ratas , Ratas Sprague-Dawley , Proteínas Represoras/genética , Transgenes , Ubiquitina/genética

RESUMEN

Here we studied the effects of glial cell line-derived neurotrophic factor (GDNF) in a rat model that represents the symptomatic stages of Parkinson's disease. GDNF was infused starting 2 weeks after an intrastriatal 6-hydroxydopamine (6-OHDA) lesion in order to halt the ongoing degeneration of the nigrostriatal dopaminergic neurons. GDNF or vehicle was infused in the striatum or the lateral ventricle via an osmotic minipump over a total 4-week period (2-6 weeks postlesion). Motor function was evaluated by the stepping, paw reaching and drug-induced motor asymmetry tests before the pump infusion was initiated, and was repeated once during (5 weeks postlesion) and twice after the withdrawal of the minipumps (7 and 11 weeks postlesion). We found that within two weeks following the lesion approximately 40% of the nigral TH-positive neurons were lost. In the vehicle infusion groups there was an additional 20% cell loss between 2 and 12 weeks after the lesion. This latter cell loss occurred mainly in the caudal part of the SN whereas the cell loss in the rostral SN was almost complete within the first two weeks. Ventricular GDNF infusion completely blocked the late degenerating neurons in the caudal SN and had long lasting behavioural effects on the stepping test and amphetamine rotation, extending to 6 weeks after withdrawal of the factor. Striatal infusion affected the motor behaviour transiently during the infusion period but the motor performance of these animals returned to baseline upon cessation of the GDNF delivery, and the delayed nigral cell loss was marginally affected. We conclude that intraventricular GDNF can successfully block the already initiated degenerative process in the substantia nigra, and that the effects achieved via the striatal route, when GDNF is given acutely after the lesion, diminish as the fibre terminal degeneration proceeds.

Asunto(s)

Actividad Motora/efectos de los fármacos , Factores de Crecimiento Nervioso , Proteínas del Tejido Nervioso/farmacología , Enfermedad de Parkinson/fisiopatología , Anfetamina/farmacología , Animales , Cuerpo Estriado/enzimología , Cuerpo Estriado/patología , Dopamina/metabolismo , Femenino , Factor Neurotrófico Derivado de la Línea Celular Glial , Bombas de Infusión , Inyecciones Intraventriculares , Degeneración Nerviosa/inducido químicamente , Degeneración Nerviosa/patología , Oxidopamina , Enfermedad de Parkinson/patología , Enfermedad de Parkinson Secundaria/inducido químicamente , Ratas , Ratas Sprague-Dawley , Rotación , Conducta Estereotipada/fisiología , Sustancia Negra/efectos de los fármacos , Sustancia Negra/metabolismo , Factores de Tiempo , Tirosina 3-Monooxigenasa/metabolismo

RESUMEN

This study was designed to determine whether induction and phosphorylation of the transcription factor c-Jun is associated with lesion-induced death of dopaminergic neurons of the substantia nigra pars compacta, and if this cellular response is modulated by glial-cell-line-derived neurotrophic factor. In adult rats, delayed dopaminergic neuron cell death induced by intrastriatal 6-hydroxydopamine injection led to a marked increase in the number of both c-Jun- and phosphorylated c-Jun-immunoreactive nuclei in the substantia nigra pars compacta. The response was maximal before any significant loss of nigral neurons could be detected (on day 7 post lesion) and was confined to the dopaminergic neurons. Similarly, 6-hydroxydopamine lesion of the striatal dopaminergic terminals or excitotoxic lesion of the striatal target neurons in neonatal rats resulted in an increased number of c-Jun- and phosphorylated c-Jun-immunoreactive nigral nuclei that preceded the loss of nigral dopaminergic neurons. By contrast, after an excitotoxic lesion of the striatal target neurons in the adult rat, resulting in atrophy but not cell death of the nigral dopaminergic neurons, no upregulation of either c-Jun or phosphorylated c-Jun was found. A single injection of 10 microg of glial-cell-line-derived-neurotrophic factor given at day 3 after the intrastriatal 6-hydroxydopamine lesion reduced the number of c-Jun- and phosphorylated c-Jun-immunoreactive nuclei in the substantia nigra and protected the dopaminergic neurons from the ensuing cell death. We conclude that c-Jun induction and phosphorylation may be involved in the cellular events leading to death of nigral dopaminergic neurons in vivo and that this response can be modulated by glial-cell-line-derived-neurotrophic factor.

Asunto(s)

Encefalopatías/metabolismo , Dopamina/metabolismo , Factores de Crecimiento Nervioso , Neuronas/metabolismo , Proteínas Proto-Oncogénicas c-jun/metabolismo , Sustancia Negra/metabolismo , Envejecimiento/fisiología , Animales , Animales Recién Nacidos/crecimiento & desarrollo , Animales Recién Nacidos/fisiología , Encefalopatías/inducido químicamente , Encefalopatías/patología , Muerte Celular , Femenino , Factor Neurotrófico Derivado de la Línea Celular Glial , Masculino , Proteínas del Tejido Nervioso/farmacología , Neuronas/efectos de los fármacos , Neuronas/fisiología , Neurotoxinas , Oxidopamina , Fosforilación/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Sustancia Negra/patología

RESUMEN

During the last few years, recombinant viral vectors derived from adenovirus (Ad), adeno-associated virus (AAV) or lentivirus (LV) have been developed into highly effective vehicles for gene transfer to the adult central nervous system. In recent experiments, in the rat model of Parkinson's disease, all three vector systems have been shown to be effective for long-term delivery of glial cell line-derived neurotrophic factor (GDNF) at biologically relevant levels in the nigrostriatal system. Injection of the GDNF encoding vectors into either striatum or substantia nigra thus makes it possible to obtain a regionally restricted over-expression of GDNF within the nigrostriatal system that is sufficient to block the toxin-induced degeneration of the nigral dopamine neurons. Injection of GDNF vectors in the striatum, in particular, is effective not only in rescuing the cell bodies in the substantia nigra, but also in preserving the nigrostriatal projection and a functional striatal dopamine innervation in the rat Parkinson model. Long-term experiments using AAV-GDNF and LV-GDNF vectors show, moreover, that sustained GDNF delivery over 3-6 months can promote regeneration and significant functional recovery in both 6-OHDA-lesioned rats and MPTP-lesioned monkeys. The impressive efficacy of the novel AAV and LV vectors in rodent and primate Parkinson models suggests that the time may now be ripe to explore these vector systems as tools for neuroprotective treatments in patients with Parkinson's disease.

Asunto(s)

Técnicas de Transferencia de Gen , Terapia Genética/métodos , Vectores Genéticos/administración & dosificación , Factores de Crecimiento Nervioso , Proteínas del Tejido Nervioso/administración & dosificación , Enfermedad de Parkinson Secundaria/terapia , 1-Metil-4-fenil-1,2,3,6-Tetrahidropiridina , Adenoviridae/genética , Adenoviridae/inmunología , Animales , Supervivencia Celular/efectos de los fármacos , Cuerpo Estriado/efectos de los fármacos , Cuerpo Estriado/metabolismo , Cuerpo Estriado/patología , Dependovirus/genética , Modelos Animales de Enfermedad , Expresión Génica , Vectores Genéticos/efectos adversos , Vectores Genéticos/genética , Vectores Genéticos/metabolismo , Factor Neurotrófico Derivado de la Línea Celular Glial , Haplorrinos , Inflamación/etiología , Inflamación/inmunología , Lentivirus/genética , Microinyecciones , Proteínas del Tejido Nervioso/biosíntesis , Proteínas del Tejido Nervioso/genética , Oxidopamina , Enfermedad de Parkinson Secundaria/inducido químicamente , Enfermedad de Parkinson Secundaria/metabolismo , Ratas , Sustancia Negra/efectos de los fármacos , Sustancia Negra/metabolismo , Sustancia Negra/patología , Resultado del Tratamiento

RESUMEN

Here we studied whether glial cell line-derived neurotrophic factor (GDNF), given as a single bolus injection before an intrastriatal 6-hydroxydopamine (6-OHDA) lesion, can protect the nigrostriatal dopamine neurons against the toxin-induced damage and preserve normal motor functions in the lesioned animals. GDNF or vehicle was injected in the striatum (25 microg), substantia nigra (25 microg) or lateral ventricle (50 microg) 6 h before the 6-OHDA lesion (20 microg/3 microL). Motor function was evaluated by the stepping and drug-induced motor asymmetry tests. Lesioned animals given vehicle alone showed a clear ipsilateral-side bias in response to amphetamine (13 turns/min), a moderate contralateral-side bias to apomorphine (4.5 turns/min) and a moderate to severe stepping deficit on the contralateral forepaw (three to four steps, as compared with 11-13 steps on the unimpaired side). Injection of GDNF into the striatum had a significant protective effect both on nigrostriatal function (1-2 turns/min in the rotation tests and seven to eight steps in the stepping test), and the integrity of the nigrostriatal pathway, seen as a protection of both the cell bodies in the substantia nigra and the dopamine innervation in the striatum. Injection of GDNF in the nigra had a protective effect on the nigral cell bodies, but not the striatal innervation, and failed to provide any functional benefit. In contrast, intranigral GDNF had deleterious effects on both the striatal TH-positive fibre density and on drug-induced rotation tests. Intraventricular injection had no effect. We conclude that preservation of normal motor functions in the intrastriatal 6-OHDA lesion model requires protection of striatal terminal innervation, and that this can be achieved by intrastriatal, but not nigral or intraventricular, administration of GDNF.

Asunto(s)

Ventrículos Cerebrales/fisiología , Cuerpo Estriado/fisiología , Dopamina/fisiología , Fibras Nerviosas/fisiología , Factores de Crecimiento Nervioso , Proteínas del Tejido Nervioso/farmacología , Neuronas/fisiología , Fármacos Neuroprotectores/farmacología , Sustancia Negra/fisiología , Animales , Apomorfina/administración & dosificación , Apomorfina/farmacología , Ventrículos Cerebrales/efectos de los fármacos , Cuerpo Estriado/efectos de los fármacos , Cuerpo Estriado/patología , Femenino , Lateralidad Funcional , Factor Neurotrófico Derivado de la Línea Celular Glial , Inyecciones Intraventriculares , Microinyecciones , Actividad Motora/efectos de los fármacos , Fibras Nerviosas/efectos de los fármacos , Fibras Nerviosas/ultraestructura , Proteínas del Tejido Nervioso/administración & dosificación , Neuronas/efectos de los fármacos , Fármacos Neuroprotectores/administración & dosificación , Oxidopamina , Ratas , Ratas Sprague-Dawley , Sustancia Negra/efectos de los fármacos , Tirosina 3-Monooxigenasa/análisis

RESUMEN

Immature progenitor cells (generated by in vitro propagation) may provide a useful alternative to primary cells (from dissected embryonic tissue) for transplantation if their migratory and proliferative and differentiation properties can be controlled and directed in vivo. In this study E15 murine EGF-responsive progenitor cells were transplanted to the striatum of adult rats. Simultaneously, these animals received continuous infusion of either epidermal growth factor (EGF) or vehicle, to the lateral ventricle, for 8 days. In animals that received EGF, the transplanted progenitors migrated toward the lateral ventricle and proliferated, as evidenced by bromodeoxyuridine incorporation. Progenitor cells transplanted to rats that received vehicle infusions showed neither of these responses. In all animals, transplanted progenitors expressed an immature astrocyte or oligodendrocyte phenotype, the majority of cells being astrocytes. We conclude that EGF stimulates the migration and proliferation of murine progenitor cells in vivo, either directly or indirectly, but does not influence their phenotypic differentiation.

Asunto(s)

Diferenciación Celular/efectos de los fármacos , Movimiento Celular/efectos de los fármacos , Cuerpo Estriado/efectos de los fármacos , Factor de Crecimiento Epidérmico/farmacología , Trasplante de Tejido Fetal , Células Madre/efectos de los fármacos , Animales , Diferenciación Celular/fisiología , División Celular/efectos de los fármacos , División Celular/fisiología , Movimiento Celular/fisiología , Células Cultivadas , Cuerpo Estriado/fisiología , Factor de Crecimiento Epidérmico/fisiología , Femenino , Trasplante de Tejido Fetal/fisiología , Ventrículos Laterales/efectos de los fármacos , Ventrículos Laterales/fisiología , Ratones , Ratones Transgénicos , Ratas , Ratas Sprague-Dawley , Trasplante de Células Madre , Células Madre/fisiología

RESUMEN

Previous studies have used recombinant adeno-associated viral (rAAV) vectors to deliver glial cell line-derived neurotrophic factor (GDNF) in the substantia nigra to protect the nigral dopamine (DA) neurons from 6-hydroxydopamine-induced damage. However, no regeneration or functional recovery was observed in these experiments. Here, we have used an rAAV-GDNF vector to express GDNF long-term (6 months) in either the nigral DA neurons themselves, in the striatal target cells, or in both of these structures. The results demonstrate that both nigral and striatal transduction provide significant protection of nigral DA neurons against the toxin-induced degeneration. However, only the rats receiving rAAV-GDNF in the striatum displayed behavioral recovery, accompanied by significant reinnervation of the lesioned striatum, which developed gradually over the first 4-5 months after the lesion. GDNF transgene expression was maintained at high levels throughout this period. These results provide evidence that rAAV is a highly efficient vector system for long-term expression of therapeutic proteins in the nigrostriatal system.

Asunto(s)

Cuerpo Estriado/fisiopatología , Técnicas de Transferencia de Gen , Terapia Genética , Factores de Crecimiento Nervioso , Regeneración Nerviosa/fisiología , Proteínas del Tejido Nervioso/genética , Fármacos Neuroprotectores , Trastornos Parkinsonianos/terapia , Sustancia Negra/fisiopatología , Animales , Benzazepinas/farmacología , Cuerpo Estriado/efectos de los fármacos , Dependovirus , Agonistas de Dopamina/farmacología , Femenino , Genes Reporteros , Vectores Genéticos , Factor Neurotrófico Derivado de la Línea Celular Glial , Proteínas Fluorescentes Verdes , Proteínas Luminiscentes/análisis , Proteínas Luminiscentes/genética , Proteínas del Tejido Nervioso/fisiología , Oxidopamina/toxicidad , Trastornos Parkinsonianos/fisiopatología , Ratas , Ratas Sprague-Dawley , Transducción de Señal , Sustancia Negra/efectos de los fármacos , Tirosina 3-Monooxigenasa/análisis

RESUMEN

Glial cell line-derived neurotrophic factor (GDNF) has prominent survival-promoting effects on lesioned nigrostriatal dopamine neurons, but understanding of the conditions under which functional recovery can be obtained remains to be acquired. We report here the time course of nigrostriatal axon degeneration in the partial lesion model of Parkinson's disease and the morphological and functional effects of sequential administration of GDNF in the substantia nigra (SN) and striatum during the first 5 weeks postlesion. By 1 day postlesion, the nigrostriatal axons had retracted back to the level of the caudal globus pallidus. Over the next 6 days axonal retraction progressed down to the SN, and during the following 7 weeks 74% of tyrosine hydroxylase-positive (TH(+)) and 84% of retrogradely labeled nigral neurons were lost, with a more pronounced loss in the rostral part of the SN. GDNF administration protected 70 and 72% of the nigral TH(+) and retrogradely labeled cell bodies, respectively, but did not prevent the die-back of the lesioned nigrostriatal axons. Although clear signs of sprouting were observed close to the injection site in the striatum as well as in the globus pallidus, the overall DA innervation of the striatum [as measured by [(3)H]-N-[1-(2-benzo(b)thiopenyl)cyclohexyl]piperidine-binding autoradiography] was not improved by the GDNF treatment. Moreover, the lesion-induced deficits in forelimb akinesia and drug-induced rotation were not attenuated. We conclude that functional recovery in the partial lesion model depends not only on preservation of the nigral cell bodies, but more critically on the ability of GDNF to promote significant reinnervation of the denervated striatum.

Asunto(s)

Axones/efectos de los fármacos , Cuerpo Estriado/efectos de los fármacos , Dopamina/metabolismo , Factores de Crecimiento Nervioso , Proteínas del Tejido Nervioso/farmacología , Neuronas/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Sustancia Negra/efectos de los fármacos , Animales , Transporte Axonal , Axones/fisiología , Axones/ultraestructura , Peso Corporal/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Cuerpo Estriado/citología , Cuerpo Estriado/fisiología , Femenino , Miembro Anterior/inervación , Factor Neurotrófico Derivado de la Línea Celular Glial , Microinyecciones , Actividad Motora/efectos de los fármacos , Degeneración Nerviosa/inducido químicamente , Degeneración Nerviosa/patología , Degeneración Nerviosa/fisiopatología , Regeneración Nerviosa , Proteínas del Tejido Nervioso/administración & dosificación , Neuronas/citología , Neuronas/fisiología , Fármacos Neuroprotectores/administración & dosificación , Oxidopamina/toxicidad , Prosencéfalo/efectos de los fármacos , Prosencéfalo/fisiología , Ratas , Ratas Sprague-Dawley , Sustancia Negra/citología , Sustancia Negra/fisiología , Factores de Tiempo , Tirosina 3-Monooxigenasa/metabolismo

RESUMEN

The glial cell line-derived neurotrophic factor (GDNF)-family of neurotrophic factors consisted until recently of three members, GDNF, neurturin, and persephin. We describe here the cloning of a new GDNF-family member, neublastin (NBN), identical to artemin (ART), recently published (Baloh et al., 1998). Addition of NBN/ART to cultures of fetal mesencephalic dopamine (DA) neurons increased the number of surviving tyrosine hydroxylase (TH)-immunoreactive neurons by approximately 70%, similar to the maximal effect obtained with GDNF. To investigate the neuroprotective effects in vivo, lentiviral vectors carrying the cDNA for NBN/ART or GDNF were injected into the striatum and ventral midbrain. Three weeks after an intrastriatal 6-hydroxydopamine lesion only about 20% of the nigral DA neurons were left in the control group, while 80-90% of the DA neurons remained in the NBN/ART and GDNF treatment groups, and the striatal TH-immunoreactive innervation was partly spared. We conclude that NBN/ART, similarly to GDNF, is a potent neuroprotective factor for the nigrostriatal DA neurons in vivo.

Asunto(s)

Cuerpo Estriado/citología , Dopamina/fisiología , Factores de Crecimiento Nervioso/fisiología , Proteínas del Tejido Nervioso/fisiología , Neuronas/citología , Neuronas/fisiología , Sustancia Negra/citología , Tirosina 3-Monooxigenasa/análisis , Secuencia de Aminoácidos , Animales , Línea Celular , Células Cultivadas , Clonación Molecular , Técnicas de Transferencia de Gen , Vectores Genéticos , Factor Neurotrófico Derivado de la Línea Celular Glial , Humanos , Lentivirus , Ratones , Datos de Secuencia Molecular , Factores de Crecimiento Nervioso/genética , Proteínas del Tejido Nervioso/química , Proteínas del Tejido Nervioso/genética , Fármacos Neuroprotectores , Ratas , Alineación de Secuencia , Homología de Secuencia de Aminoácido

RESUMEN

A major obstacle in ex vivo gene transfer has been the loss of transgene expression soon after implantation of the grafted transduced cells. Recently, a lentiviral vector system has been developed which has proven to express high levels of transgenes in vivo after direct injection into the tissue. In this study, we have investigated the use of such a vector for ex vivo gene transfer to the brain. A number of neural cell types were found to be permissive to transduction by the lentiviral vector in vitro and a majority of them expressed the transgene after transplantation to the rat brain. Transgene expression was detected up to 8 weeks post-grafting. These findings suggest that recombinant lentiviral vectors may be used for further development of ex vivo gene therapy protocols to the CNS.

Asunto(s)

Encéfalo/virología , Técnicas de Transferencia de Gen , Vectores Genéticos/genética , Lentivirus/genética , Transgenes/genética , Animales , Trasplante de Tejido Encefálico , Diferenciación Celular/genética , Células Cultivadas/citología , Células Cultivadas/metabolismo , Células Cultivadas/trasplante , ADN Recombinante/genética , Regulación Viral de la Expresión Génica/fisiología , Terapia Genética/tendencias , Proteínas Fluorescentes Verdes , Humanos , Proteínas Luminiscentes/genética , Ratones , Ratas , Trasplante de Células Madre , Células Madre/citología , Células Madre/metabolismo , Transducción Genética

RESUMEN

We investigated here the effect of the novel glial cell line-derived neurotrophic factor (GDNF)-family member neurturin (NTN) on transplanted fetal dopamine (DA) neurons. Three groups of rats with complete unilateral 6-hydroxydopamine (6-OHDA) lesions of the nigrostriatal DA system received intrastriatal grafts of embryonic ventral mesencephalic tissue. Following transplantation animals received repeated injections of vehicle or NTN (0.3 microg or 3.0 microg) over three weeks posttransplantation. NTN-treated animals had significantly (1.8-fold) more tyrosine hydroxylase-immunoreactive (TH-IR) neurons. Graft volume, TH-IR cell volume and overall dopaminergic host reinnervation remained unchanged. Amphetamine-induced rotation was rapidly compensated in all grafted rats. We conclude that administration of NTN may be a powerful way to increase survival of transplanted fetal DA neurons.

Asunto(s)

Dopamina/metabolismo , Supervivencia de Injerto/efectos de los fármacos , Neostriado/cirugía , Factores de Crecimiento Nervioso/farmacología , Neuronas/trasplante , Anfetamina/farmacología , Animales , Inhibidores de Captación de Dopamina/farmacología , Femenino , Inmunohistoquímica , Mesencéfalo/citología , Mesencéfalo/embriología , Neostriado/enzimología , Fibras Nerviosas/fisiología , Neuronas/metabolismo , Neurturina , Ratas , Ratas Sprague-Dawley , Conducta Estereotipada/efectos de los fármacos , Tirosina 3-Monooxigenasa/metabolismo

RESUMEN

Both glial cell line-derived neurotrophic factor (GDNF) and its recently discovered congener, neurturin (NTN), have been shown to exert neuroprotective effects on lesioned nigral dopamine (DA) neurons when administered at the level of the substantia nigra. In the present study, we have explored the relative in vivo potency of these two neurotrophic factors using two alternative routes of administration, into the striatum or the lateral ventricle, which may be more relevant in a clinical setting. In rats subjected to an intrastriatal (IS) 6-hydroxydopamine (6-OHDA) lesion, GDNF and NTN were injected every third day for 3 weeks starting on the day after the 6-OHDA injection. GDNF provided almost complete (90-92%) protection of the lesioned nigral DA neurons after both IS and intracerebroventricular (ICV) administration. NTN, by contrast, was only partially effective after IS injection (72% sparing) and totally ineffective after ICV injection. Although the trophic factor injections protected the nigral neurons from lesion-induced cell death, the level of expression of the phenotypic marker, tyrosine hydroxylase (TH), was markedly reduced in the rescued cell bodies. The extent of 6-OHDA-induced DA denervation in the striatum was unaffected by both types of treatment; consistent with this observation, the high rate of amphetamine-induced turning seen in the lesioned control animals was unaltered by either GDNF or NTN treatment. In the GDNF-treated animals, and to a lesser extent also after IS NTN treatment, prominent axonal sprouting was observed within the globus pallidus, at the level where the lesioned nigrostriatal axons are known to end at the time of onset of the neurotrophic factor treatment. The results show that GDNF is highly effective as a neuroprotective and axon growth-stimulating agent in the IS 6-OHDA lesion model after both IS and ICV administration. The lower efficacy of NTN after IS, and particularly ICV, administration may be explained by the poor solubility and diffusion properties at neutral pH.

Asunto(s)

Factores de Crecimiento Nervioso/farmacología , Regeneración Nerviosa/fisiología , Proteínas del Tejido Nervioso/farmacología , Neuronas/citología , Fármacos Neuroprotectores/farmacología , Enfermedad de Parkinson Secundaria/patología , Sustancia Negra/patología , Anfetamina/farmacología , Animales , Anticuerpos , Apomorfina/farmacología , Atrofia , Peso Corporal , Ventrículos Cerebrales/citología , Cuerpo Estriado/citología , Dopamina/fisiología , Dopaminérgicos/farmacología , Agonistas de Dopamina/farmacología , Proteínas ELAV , Femenino , Factor Neurotrófico Derivado de la Línea Celular Glial , Concentración de Iones de Hidrógeno , Inyecciones Intraventriculares , Degeneración Nerviosa/inducido químicamente , Degeneración Nerviosa/fisiopatología , Neuronas/efectos de los fármacos , Neuronas/enzimología , Neurturina , Oxidopamina , Proteínas de Unión al ARN/análisis , Ratas , Ratas Sprague-Dawley , Simpaticolíticos , Tirosina 3-Monooxigenasa/análisis , Tirosina 3-Monooxigenasa/inmunología

RESUMEN

Reactive oxygen species are thought to be involved in the death of dopaminergic neurons in Parkinson's disease as well as in transplanted embryonic dopaminergic neurons. The spin-trap agent alpha-phenyl-N-tert-butyl nitrone (PBN) reacts directly with radical species and may thereby prevent them from damaging important cellular molecules such as membrane lipids. We found that PBN does not increase the survival of cultured embryonic dopaminergic neurons subjected to serum deprivation, whereas the antioxidant and lipid peroxidation inhibitor lazaroid U-83836E does. Moreover, PBN does not increase the survival of grafted embryonic dopaminergic neurons or graft efficacy (monitored as changes in drug-induced motor asymmetry in hemiparkinsonian rats) when the spin-trap agent is given intraperitoneally to the graft recipient or is added to the solutions used when preparing tissue for transplantation. Another spin-trap agent, alpha-(4-pyridyl-1-oxide)-N-tert-butyl nitrone (POBN) also failed to protect neurons when given to graft recipients in the same experimental paradigm. Finally, we found that adult nigral neurons subjected to a progressive retrograde 6-OHDA lesion are not protected by systemic treatment with PBN. Even though reduction of oxidative stress by overexpression of superoxide dismutase or addition of lazaroids have previously been shown to enhance the survival of cultured and grafted dopaminergic neurons, spin-trap agents PBN and POBN do not provide protection in these experimental paradigms. This may be due to antioxidants and spin-trap agents interfering in different steps of free radical-induced cell damage.

Asunto(s)

Dopamina/metabolismo , Neuronas/efectos de los fármacos , Neuronas/fisiología , Óxidos de Nitrógeno/farmacología , Envejecimiento/fisiología , Animales , Supervivencia Celular/efectos de los fármacos , Trasplante de Células , Células Cultivadas , Óxidos N-Cíclicos , Femenino , Trasplante de Tejido Fetal , Supervivencia de Injerto/efectos de los fármacos , Mesencéfalo/citología , Mesencéfalo/embriología , Neuronas/patología , Enfermedad de Parkinson Secundaria/cirugía , Ratas , Ratas Sprague-Dawley , Marcadores de Spin , Sustancia Negra/patología

RESUMEN

Partial lesions of the nigrostriatal dopamine system have been investigated with respect to their ability to induce consistent long-lasting deficits in movement initiation and skilled forelimb use. In eight different lesion groups 6-hydroxydopamine (6-OHDA) was injected at one, two, three, or four sites into the lateral sector of the right striatum, in a total dose of 20-30 microgram. Impairments in movement initiation in a forelimb stepping test, and in skilled paw use in a paw-reaching test, was seen only in animals where the severity of the lesion exceeded a critical threshold, which was different for the different tests used: single (1 x 20 microgram) or two-site (2 x 10 microgram) injections into the striatum had only small affects on forelimb stepping, no effect on skilled paw use. More pronounced deficits were obtained in animals where the same total dose of 6-OHDA was distributed over three or four sites along the rostro-caudal extent of the lateral striatum or where the injections were made close to the junction of the globus pallidus. The results show that a 60-70% reduction in tyrosine hydroxylase (TH)-positive fiber density in the lateral striatum, accompanied by a 50-60% reduction in TH-positive cells in substantia nigra (SN), is sufficient for the induction of significant impairment in initiation of stepping. Impaired skilled paw-use, on the other hand, was obtained only with a four-site (4 x 7 microgram) lesion, which induced 80-95% reduction in TH fiber density throughout the rostrocaudal extent of the lateral striatum and a 75% loss of TH-positive neurons in SN. Drug-induced rotation, by contrast, was observed also in animals with more restricted presymptomatic lesions. The results indicate that the four-site intrastriatal 6-OHDA lesion may be a relevant model of the neuropathology seen in parkinsonian patients in a manifest symptomatic stage of the disease and may be particularly useful experimentally since it leaves a significant portion of the nigrostriatal projection intact which can serve as a substrate for regeneration and functional recovery in response to growth promoting and neuroprotective agents.

Asunto(s)

Cuerpo Estriado/fisiología , Dopamina/fisiología , Actividad Motora/fisiología , Degeneración Nerviosa/fisiopatología , Desempeño Psicomotor/fisiología , Sustancia Negra/fisiología , Anfetamina/farmacología , Animales , Apomorfina/farmacología , Femenino , Miembro Anterior/inervación , Microinyecciones , Actividad Motora/efectos de los fármacos , Neuronas/enzimología , Oxidopamina , Ratas , Ratas Sprague-Dawley , Rotación , Tirosina 3-Monooxigenasa/análisis

RESUMEN

Glial cell line-derived neurotrophic factor (GDNF) exhibits potent effects on survival and function of midbrain dopaminergic (DA) neurons in a variety of models. Although other growth factors expressed in the vicinity of developing DA neurons have been reported to support survival of DA neurons in vitro, to date none of these factors duplicate the potent and selective actions of GDNF in vivo. We report here that neurturin (NTN), a homolog of GDNF, is expressed in the nigrostriatal system, and that NTN exerts potent effects on survival and function of midbrain DA neurons. Our findings indicate that NTN mRNA is sequentially expressed in the ventral midbrain and striatum during development and that NTN exhibits survival-promoting actions on both developing and mature DA neurons. In vitro, NTN supports survival of embryonic DA neurons, and in vivo, direct injection of NTN into the substantia nigra protects mature DA neurons from cell death induced by 6-OHDA. Furthermore, administration of NTN into the striatum of intact adult animals induces behavioral and biochemical changes associated with functional upregulation of nigral DA neurons. The similarity in potency and efficacy of NTN and GDNF on DA neurons in several paradigms stands in contrast to the differential distribution of the receptor components GDNF Family Receptor alpha1 (GFRalpha1) and GFRalpha2 within the ventral mesencephalon. These results suggest that NTN is an endogenous trophic factor for midbrain DA neurons and point to the possibility that GDNF and NTN may exert redundant trophic influences on nigral DA neurons acting via a receptor complex that includes GFRalpha1.

Asunto(s)

Cuerpo Estriado/citología , Dopamina/fisiología , Factores de Crecimiento Nervioso/genética , Neuronas/citología , Sustancia Negra/citología , Ácido 3,4-Dihidroxifenilacético/análisis , Animales , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/fisiología , Células Cultivadas , Cuerpo Estriado/embriología , Modelos Animales de Enfermedad , Dopamina/análisis , Regulación del Desarrollo de la Expresión Génica/fisiología , Factor Neurotrófico Derivado de la Línea Celular Glial , Ratones , Factores de Crecimiento Nervioso/farmacología , Proteínas del Tejido Nervioso/farmacología , Neuronas/química , Neuronas/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Neurturina , Núcleo Accumbens/citología , Núcleo Accumbens/embriología , Oxidopamina , Enfermedad de Parkinson Secundaria/tratamiento farmacológico , Enfermedad de Parkinson Secundaria/patología , ARN Mensajero/análisis , Sustancia Negra/embriología , Simpaticolíticos

RESUMEN

The ability of intrastriatally-administered glial cell line-derived neurotrophic factor to induce reinnervation and functional recovery in the partially-lesioned nigrostriatal dopamine system was explored in rats subjected to an axon terminal lesion induced by injection of 6-hydroxydopamine into the striatum. Glial cell line-derived neurotrophic factor was administered as multiple intrastriatal injections (10 x 5 micrograms) over a three-week period starting four weeks after the 6-hydroxydopamine injection, i.e. at the time when the acute phase of degeneration of the nigral dopamine neurons is complete. In the control group the lesion induced a 75-90% reduction of the dopaminergic innervation in the dorsolateral striatum (assessed by [3H]N-[1-(2-benzo(b)thiopenyl)cyclohexyl]piperidine-labelled dopamine uptake sites), and an approximately 50% reduction in the number of tyrosine hydroxylase-positive cell bodies in the central part of the substantia nigra, accompanied by a significant impairment in spontaneous motor behaviour, as assessed by a forelimb stepping test. In the glial cell line-derived neurotrophic factor-treated animals striatal [3H]N-[1-(2-benzo(b)thiopenyl)cyclohexyl]piperidine binding was restored to 70-95% of normal and contralateral forelimb stepping was completely normalized. The extent of striatal denervation in the individual lesioned and treated animals was well correlated with the performance of the affected limb in the stepping test. These results show that intrastriatal glial cell line-derived neurotrophic factor can stimulate substantial axonal sprouting and reinnervation of the partially deafferated striatum to a degree sufficient to reverse the lesion-induced deficit in spontaneous motoric behaviour, indicating that a direct action of glial cell line-derived neurotrophic factor on spared dopaminergic afferents in the striatum may be important for functional recovery in the rat Parkinson model.

Asunto(s)

Neostriado/fisiología , Factores de Crecimiento Nervioso , Proteínas del Tejido Nervioso/farmacología , Neuronas Aferentes/fisiología , Fármacos Neuroprotectores/farmacología , Enfermedad de Parkinson Secundaria/tratamiento farmacológico , Sustancia Negra/fisiología , Animales , Autorradiografía , Desnervación , Femenino , Factor Neurotrófico Derivado de la Línea Celular Glial , Inmunohistoquímica , Inyecciones , Actividad Motora/efectos de los fármacos , Actividad Motora/fisiología , Neostriado/efectos de los fármacos , Proteínas del Tejido Nervioso/administración & dosificación , Neuronas Aferentes/efectos de los fármacos , Fármacos Neuroprotectores/administración & dosificación , Oxidopamina , Enfermedad de Parkinson Secundaria/inducido químicamente , Enfermedad de Parkinson Secundaria/fisiopatología , Ratas , Ratas Sprague-Dawley , Sustancia Negra/citología , Sustancia Negra/efectos de los fármacos , Simpaticolíticos , Tirosina 3-Monooxigenasa/metabolismo

RESUMEN

Intrastriatal 6-hydroxydopamine injections in rats induce partial lesions of the nigrostriatal dopamine (DA) system which are accompanied by a delayed and protracted degeneration of DA neurons within the substantia nigra. By careful selection of the dose and placement of the toxin it is possible to obtain reproducible and regionally defined partial lesions which are well correlated with stable functional deficits, not only in drug-induced behaviors but also in spontaneous motoric and sensorimotoric function, which are analogous to the symptoms seen in patients during early stages of Parkinson's disease. The intrastriatal partial lesion model has proved to be particularly useful for studies on the mechanisms of action of neurotrophic factors since it offers opportunities to investigate both protection of degenerating DA neurons during the acute phases after the lesion and stimulation of regeneration and functional recovery during the chronic phase of the postlesion period when a subset of the spared nigral DA neurons persist in an atrophic and dysfunctional state. In the in vivo experiments performed in this model glial cell line-derived neurotrophic factor (GDNF) has been shown to exert neurotrophic effects both at the level of the cell bodies in the substantia nigra and at the level of the axon terminals in the striatum. Intrastriatal administration of GDNF appears to be a particularly effective site for induction of axonal sprouting and regeneration accompanied by recovery of spontaneous sensorimotor behaviors in the chronically lesioned nigrostriatal dopamine system.

Asunto(s)

Factores de Crecimiento Nervioso , Regeneración Nerviosa/efectos de los fármacos , Proteínas del Tejido Nervioso/farmacología , Fármacos Neuroprotectores/farmacología , Enfermedad de Parkinson/patología , Enfermedad de Parkinson/fisiopatología , Animales , Factor Neurotrófico Derivado de la Línea Celular Glial , Humanos

RESUMEN

The ability of transplants of fetal nigral neurons to reverse symptoms in patients with Parkinson's disease is, at least in part, limited by the poor survival of the grafted dopaminergic neurons and the restricted host reinnervation from the graft. Here, we report that glial cell line-derived neurotrophic factor, a novel trophic factor for developing dopaminergic neurons, can increase survival and fibre outgrowth of fetal nigral dopaminergic neurons, and stimulate graft-induced functional recovery after transplantation in a rat model of Parkinson's disease. Injections of rat glial cell line-derived neurotrophic factor adjacent to the graft enhanced graft function, resulting in complete compensation of amphetamine-induced turning behaviour already by two weeks postgrafting as opposed to four weeks in the control group. The total number of surviving tyrosine hydroxylase-positive neurons was about two-fold greater in the glial cell line-derived neurotrophic factor-treated animals compared to the vehicle-injected controls, and the density of tyrosine hydroxylase-positive fibres was found to be increased both in the host striatum (from 37.6 +/- 8.3% to 105.5 +/- 9.7% of intact striatum) as well as inside the graft (55% increase). Moreover, in animals treated with glial cell line-derived neurotrophic factor, the outgrowth of tyrosine hydroxylase-positive fibres was mostly directed towards the injection site. These findings show that supply of exogenous glial cell line-derived neurotrophic factor to the transplantation site improves survival, growth and function of transplanted fetal nigral dopaminergic neurons in the rat Parkinson model.

Asunto(s)

Trasplante de Tejido Encefálico/fisiología , Dopamina/metabolismo , Trasplante de Tejido Fetal/fisiología , Supervivencia de Injerto/efectos de los fármacos , Factores de Crecimiento Nervioso , Proteínas del Tejido Nervioso/farmacología , Neuronas/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Sustancia Negra/trasplante , Animales , Trasplante de Tejido Encefálico/patología , División Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Modelos Animales de Enfermedad , Trasplante de Tejido Fetal/patología , Factor Neurotrófico Derivado de la Línea Celular Glial , Fibras Nerviosas/fisiología , Fibras Nerviosas/ultraestructura , Neuronas/citología , Neuronas/fisiología , Enfermedad de Parkinson/cirugía , Ratas , Sustancia Negra/citología , Sustancia Negra/fisiología , Tirosina 3-Monooxigenasa/análisis , Tirosina 3-Monooxigenasa/biosíntesis